The U.S. government has resisted calls from Big Pharma and other U.S. business sectors to take a tougher stance against India and Canada for their alleged failures to meet the U.S. standard for protection and enforcement of intellectual property.
In the 2014 Special 301 Report issued by the Office of the U.S. Trade Representative (USTR), India remained on the U.S.’s “priority watch list,” along with China and eight other countries. The U.S. Chamber of Commerce and the pharmaceutical industry had lobbied to get India tagged with the harsher designation of “priority foreign country”—a label that could have led to trade sanctions.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
